— Christine M. Kukka, Project Manager, HBV Advocate
A presentation at the 2015 AASLD and Industry Colloquium in late
March, unveiled a new potential hepatitis B treatment that uses a
two-pronged approach against HBV.
Using small molecule nucleic acid hybrid
compounds, the drug helps a patient's immune system target and attack
HBV-infected liver cells while also acting like an antiviral to slow
viral replication.
The drug, called SB 9200, was created by Spring Bank Pharmaceuticals Inc. and is taken orally.
"The compound has shown potent antiviral activity
(in laboratory experiments) against wild type- and resistant variants
of HBV and produced synergistic antiviral activity when combined with
HBV polymerase inhibitors such as tenofovir and entecavir," researchers
wrote in a press release. Phase II clinical trials for SB 9200 in
HBV-infected patients are expected to begin in late 2015.
Source: http://springbankpharm.com/spring-bank-pharmaceuticals-to-present-novel-approach-to-hepatitis-b-treatment-at-the-2015-aasld-and-industry-colloquium/
http://www.hbvadvocate.org/news/HBJ12.4.htm
Labels: experimental treatment, SB 9200
